Home  About Journal Instructions for Authors Editorial Board Subscribe Advertisement Messages Board Contact Us 中文

CJAP ›› 2016, Vol. 32 ›› Issue (3): 202-206.doi: 10.13459/j.cnki.cjap.2016.03.003

Previous Articles     Next Articles

The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway

DU Rui-xue1, YE Ping1, YAN Guang-tao2, DENG Zi-hui2, LIANG Wen-tao3, GUO Zi-kuan5, ZHANG Hong-hong4, GEN Miao4   

  1. 1. Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing 100853;
    2. Institue of Basic Medical Sciences, Chinese PLA General Hospital, Beijing 100853;
    3. Institute of Surgery, Chinese PLA General Hospital, Beijing 100853;
    4. Institute of Geriatrics, Chinese PLA General Hospital, Beijing 100853;
    5. Radiology and Immunology Institute, Academy of Military Medical Sciences, Beijing 100850, China
  • Received:2016-01-22 Revised:2016-03-07 Online:2016-05-28 Published:2018-06-12
  • Supported by:
    国家自然科学基金项目(81270941)

Abstract: Objective:To investigate the effect of rosuvastatin therapy on C-C chemokine receptor(CCR2)expression in mononuclear cells in patients with carotid atherosclerosis and explore the possible upstream mechanism. Methods:Twenty patients without previous statin treatment were enrolled. Rosuvastatin were given 5 to 20 mg/day for 3 months. At baseline and 12 weeks, lipid profile and plasma monocyte chemotactic protein-1 (MCP-1) levels were examined. The mRNA and protein expressions of CCR2 in the mononuclear cells were measured with RT-PCR and flow cytometry, respectively. The mRNA and protein expression of peroxidase proliferator-activated receptor(PPAR β) were detected with RT-PCR and Western blot, respectively. Results:After 3-months rosuvastatin treatment, the patients' low-density lipoprotein cholesterol (LDL-C) levels decreased significantly (P<0.01). Compared with baseline, the mRNA and protein expressions of CCR2 in the mononuclear cells showed significantly decrease, as well as plasma MCP-1 levels (P<0.05). Both mRNA and protein expressions of PPAR β in the mononuclear cells increased (P<0.05). Conclusion:Rosuvastatin may attenuate MCP-1/CCR2 through PPARβ upstream pathway.

Key words: rosuvastatin, atherosclerosis, CCR2, PPAR β

Copyright © 2015 CJAP, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd